{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:53:44Z","timestamp":1777910024494,"version":"3.51.4"},"reference-count":4,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"\n Purpose:<\/jats:title>\n The safety and efficacy of a novel topical ocular anesthetic (AG-920 sterile ophthalmic solution, 8%) was previously evaluated in adults. For both clinical and regulatory purposes, this new agent was evaluated in children.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n This was a Phase 3, randomized, active-controlled, single-masked, parallel-group design study in healthy pediatric subjects performed at a private practice retina clinic in the United States. The safety and anesthetic efficacy of AG-920 was compared with proparacaine\u00a0hydrochloride ophthalmic solution 0.5% in 60 children undergoing ophthalmic examinations. The primary efficacy endpoint was whether the investigator was able to perform the eye examination.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n In all subjects in each treatment group, the investigator was able to perform the eye examination without additional local anesthetic. There were no adverse events reported in this study. In both the study eye and fellow eye, there were no notable changes after dosing, and both treatment groups were similar. All external eye exams in all subjects in both treatment groups were normal.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n In this pediatric population aged 7 months to >11 years, AG-920 was therapeutically equivalent to marketed proparacaine with respect to having an ophthalmic examination performed without needing additional local anesthetic. Further, AG-920 was well tolerated, and there were no clinically significant safety findings.<\/jats:p>\n <\/jats:sec>","DOI":"10.1089\/jop.2023.0187","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T11:09:37Z","timestamp":1713784177000},"page":"293-296","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["AG-920 (Articaine) Ophthalmic Solution: A Masked, Active-Controlled Evaluation of Its Local Anesthetic Efficacy and Safety in Pediatric Patients"],"prefix":"10.1177","volume":"40","author":[{"given":"Victor H.","family":"Gonzalez","sequence":"first","affiliation":[{"name":"Valley Research Institute, McAllen, Texas."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Uram","sequence":"additional","affiliation":[{"name":"American Genomics, LLC, Hobe Sound, Florida."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Schupp","sequence":"additional","affiliation":[{"name":"CMC Turnkey Solutions, Lone Tree, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Widmann","sequence":"additional","affiliation":[{"name":"Cal Clinical Solutions, Apex, North Carolina."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary D.","family":"Novack","sequence":"additional","affiliation":[{"name":"PharmaLogic Development, Inc., San Rafael, California."},{"name":"Department of Ophthalmology & Vision Science, Davis, School of Medicine, University of California, Sacramento, California."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2022.0026"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S409241"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2017.03.005"},{"issue":"2","key":"e_1_3_3_5_2","first-page":"126","article-title":"Studies on the toxicological profile of the local anaesthetic articaine","volume":"49","author":"Leuschner J","year":"1999","unstructured":"Leuschner J, , Leblanc D. Studies on the toxicological profile of the local anaesthetic articaine. Arzneimittelforschung, 1999; 49(2):126\u2013132.","journal-title":"Arzneimittelforschung"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2023.0187","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2023.0187","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2023.0187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:46:07Z","timestamp":1777646767000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2023.0187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,6,1]]}},"alternative-id":["10.1089\/jop.2023.0187"],"URL":"https:\/\/doi.org\/10.1089\/jop.2023.0187","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}